Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000211761

Medchemexpress LLC Luvixasertib hydrochloride | 1610677-37-6 | 99.6% | 535.04 g/mol | C28H31ClN6O3 | 50 MG
SDP

Catalog No. 5000211761
Encompass_Preferred

Luvixasertib hydrochloride is a selective, orally bioavailable small-molecule inhibitor of TTK/Mps1 used for preclinical research. It inhibits TTK/Mps1 with an in vitro IC50 of 1.7 nM and has demonstrated anticancer activity in cell-based studies.

  • Selective TTK/Mps1 inhibition with IC50 of 1.7 nM.
  • Orally bioavailable scaffold suitable for in vivo studies.
  • Hydrochloride salt form improves solubility and handling.
  • High reported purity (≈99.6%) for research reproducibility.
  • Supplied in small research quantities for assay development and compound characterization.

Catalog No. 50-002-11761 Supplier Medchemexpress LLC Supplier No. HY101340A50MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Luvixasertib hydrochloride is a selective, orally bioavailable small-molecule inhibitor of TTK/Mps1 used for preclinical research. It inhibits TTK/Mps1 with an in vitro IC50 of 1.7 nM and has demonstrated anticancer activity in cell-based studies.

  • Selective TTK/Mps1 inhibition with IC50 of 1.7 nM.
  • Orally bioavailable scaffold suitable for in vivo studies.
  • Hydrochloride salt form improves solubility and handling.
  • High reported purity (≈99.6%) for research reproducibility.
  • Supplied in small research quantities for assay development and compound characterization.

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.